MAZE
Maze Therapeutics Inc (MAZE)
Healthcare • NASDAQ • $26.03+2.20%
- Symbol
- MAZE
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $26.03
- Daily Change
- +2.20%
- Market Cap
- $1.44B
- Trailing P/E
- N/A
- Forward P/E
- -7.47
- 52W High
- $53.65
- 52W Low
- $8.25
- Analyst Target
- $63.55
- Dividend Yield
- N/A
- Beta
- N/A
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC…
Company websiteResearch MAZE on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.